Scarica l'app Stockscreener
124.44
0.16%
-0.20
Dopo l'orario di chiusura:
129.22
4.78
+3.84%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Incyte Corporation (INCY) Stock Price Today: $123.13 - pluang.com
Incyte (INCY) Heads To EADV With New Skin Disease Trial Data - Yahoo Finance
Analysts Offer Insights on NA Companies: Incyte (INCY) and Coherent Corp (COHR) - The Globe and Mail
How Is Incyte’s Stock Performance Compared to Other Biotech Stocks? - Barchart.com
Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Incyte Corporation (INCY) latest stock news and headlines - Yahoo Finance UK
Incyte's Colorectal Cancer Program Remains Risky, Long-Term, RBC Says - marketscreener.com
INCY Reiterated by RBC Capital -- Price Target Maintained at $10 - GuruFocus
Incyte to present inflammation and autoimmunity data at EADV - Investing.com
Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio - Business Wire
Incyte Corporation (INCY) Stock Price, News, Quote & History - Yahoo! Finance Canada
INCY Looks 18.6% Overvalued on GF Value™ as of September 2026 - GuruFocus
Incyte Expands Skin Diseases Treatment Partnership in Australia - marketscreener.com
Incyte stock heads into the open after a 1.8% pullback - AD HOC NEWS
Specialised Therapeutics expands Incyte partnership to Australia - Investing.com
Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia - Yahoo Finance
Incyte stock gains institutional backing as Bank of America boosts position - AD HOC NEWS
Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target - Yahoo Finance
What Is Incyte Corporation (NASDAQ:INCY) Signaling Through Its Pipeline? - Kalkine Media
Incyte Stock Price Forecast. Should You Buy INCY? - StockInvest.us
Incyte stock gains as investors eye September FDA decision and pipeline catalysts - AD HOC NEWS
Incyte (NASDAQ:INCY) Combines Minervini Trend Template Strength With High-Growth Momentum - ChartMill
MIRM, INCY Stocks In Focus — Will A September 26 FDA Ruling Reward This Week’s Gains? - Stocktwits
Incyte stock heads into the open after a 2.5% gain - AD HOC NEWS
Incyte Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Incyte Insider Sold Shares Worth $2,797,629, According to a Recent SEC Filing - marketscreener.com
Incyte (INCY) R&D chief exercises options and sells 23,218 shares - stocktitan.net
Incyte Corp. (INCY) Gains 1.85% to $123.99, Holding Near the Midpoint of Its Recent RangeLow Vol ETF - careplusvn.com
Incyte: Priced For Success, With No Margin Of Safety (NASDAQ:INCY) - Seeking Alpha
Incyte (NASDAQ: INCY) executive files for potential $2.8M stock sale in 2026 - stocktitan.net
Incyte (INCY): 3 Reasons We Love This Stock - Yahoo Finance
Here's How Much $1000 Invested In Incyte 20 Years Ago Would Be Worth Today - Benzinga
Cantor Fitzgerald reiterates Neutral on Incyte stock after conference - Investing.com
Profitable Biotech Incyte Stock Forms Handle Amid Strong Institutional Accumulation - Investor's Business Daily
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte at Cantor conference: pipeline advances, post-Jakafi plan - investing.com
Incyte Announces Funding of MINJUVI® (tafasitamab) for patients with Relapsed or Refractory Follicular Lymphoma through Ontario's FAST Program - Yahoo Finance
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte at Wells Fargo healthcare conference: pipeline aims to reshape growth - Investing.com India
Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup - ChartMill
Incyte Corp. (INCY) Peer Comparison – Compare with Others - Value Research
Incyte Corp. (INCY) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Incyte (INCY) Institutional Ownership 2026 $INCY - MarketBeat
Incyte Corp. (INCY) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
H.C. Wainwright reiterates Incyte stock rating on Medicaid pricing deal - Investing.com
Incyte to Present at Upcoming Investor Conferences - Yahoo Finance
BMO reiterates Incyte stock rating on CMS pricing agreement - Investing.com
Incyte (INCY) Enters Agreement With CMS to Improve Medicaid Acce - GuruFocus
Incyte agrees CMS pricing deal for Jakafi, avoids certain future mandates; no change to 2026 guidance - TradingView
Incyte (NASDAQ: INCY) expects to sidestep new CMS drug pricing rules - Stock Titan
Incyte Corporation Enters Agreement with U.S. Centers for Medicare & Medicaid Services - marketscreener.com
Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks - Yahoo Finance
Incyte (INCY) Just Moved, So What Is Drawing Attention Now? - Yahoo Finance
Incyte (INCY) Nears New ESMO Data For KRAS G12D Candidate 734 - Yahoo Finance
Incyte Corp. stock underperforms Friday when compared to competitors - MarketWatch
Incyte stock price target maintained at $150 by H.C. Wainwright - Investing.com
Incyte (NASDAQ: INCY) HR chief holds 10,993 shares after tax withholding - stocktitan.net
Incyte Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Incyte president Pablo Cagnoni sells $1.36m of INCY shares By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Here’s How Much You Would Have Made Owning Incyte Stock In The Last 20 Years - Benzinga
Insider Selling: Incyte (NASDAQ:INCY) Insider Sells $1,356,173.56 in Stock - MarketBeat
1.11%
1.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):